Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Pfizer |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00709696 |
The purpose of this study is to test the ways that a drug called varenicline helps smokers to quit smoking. Varenicline is also called Chantix® and is approved by the United States Food and Drug Administration (FDA) to help people quit smoking. We will test how varenicline works by having you quit smoking and complete tasks that assess how you think and feel. We predict that varenicline help reduce anxiety, improve attention and concentration, and reduce how satisfying cigarettes are.
Condition | Intervention |
---|---|
Nicotine Dependence |
Drug: Placebo Drug: Varenicline |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Human Laboratory Study Of Varenicline in Smokers |
Estimated Enrollment: | 20 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | November 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Placebo Varenicline
|
Drug: Placebo
Days 1 - 3 (.5 mg tablet, q.d.), Days 4 - 7 (.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
|
2: Active Comparator
Varenicline
|
Drug: Varenicline
Days 1 - 3 (.5 mg tablet, q.d.), Days 4 - 7 (.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
|
The purpose of this study is to understand the therapeutic mechanisms of varenicline, a novel nicotinic analogue, through focused measures of potential psychological and physiological mediators. Varenicline is an FDA-approved pharmacotherapy for smoking cessation that is believed to provide relief from craving and withdrawal through agonism and antagonism of some central nervous system nicotinic acetylcholinergic receptors. However, no controlled studies have established the physiological and psychological processes that mediate the efficacy of varenicline in humans. The main goal of the proposed pilot study is to evaluate and compare the effects of varenicline on subjective, cognitive, and physiological outcomes, using a randomized, placebo-controlled, double-blind between-groups design. The study will combine both brief clinical trial methodology with human laboratory approaches. A secondary goal is to validate the utility of the laboratory paradigms for the identification of future smoking cessation agents.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
1.1. Who. Subjects will be women and men between the ages of 18 and 40 who have smoked at least 10 cigarettes per day for at least 1 year. They will respond to requests in the public media for individuals who are interested in quitting smoking.
1.2. Total sample/Number per group. The total randomized sample size will equal 20 subjects, equally distributed across the two medication groups.
1.3. Inclusion Criteria.
Females who are of childbearing potential must practice effective contraception and meet the following criteria:
Exclusion Criteria:
Contact: Andrew Oliver, B.A. | 612-627-4905 | oliv0190@umn.edu |
Contact: Marc E. Mooney, Ph.D. | 612-627-1822 | moon0078@umn.edu |
United States, Minnesota | |
Tobacco Use Research Center | Recruiting |
Minneapolis, Minnesota, United States, 55414 | |
Contact: Andrew Oliver, B.A. 612-627-4905 oliv0190@umn.edu | |
Contact: Marc Mooney, Ph.D. 612-627-1822 moon0078@umn.edu | |
Principal Investigator: Marc E Mooney, Ph.D. | |
Sub-Investigator: Dorothy K Hatsukami, Ph.D. |
Principal Investigator: | Marc E Mooney, Ph.D. | University of Minnesota |
Study Director: | Andrew Oliver, Ph.D. | University of Minnesota |
Responsible Party: | University of Minnesota ( Marc E. Mooney, Ph.D. ) |
Study ID Numbers: | 0702M02324, NIDA K01-DA019446 |
Study First Received: | July 1, 2008 |
Last Updated: | July 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00709696 |
Health Authority: | United States: Federal Government |
Tobacco nicotine smoking varenicline human laboratory study |
stress tolerance startle response cognitive assessment progressive ratio |
Nicotine polacrilex Smoking Nicotine Mental Disorders |
Tobacco Use Disorder Substance-Related Disorders Disorders of Environmental Origin Stress |